EA201171098A1 - 8-замещенные хинолины и родственные аналоги в качестве модуляторов сиртуина - Google Patents
8-замещенные хинолины и родственные аналоги в качестве модуляторов сиртуинаInfo
- Publication number
- EA201171098A1 EA201171098A1 EA201171098A EA201171098A EA201171098A1 EA 201171098 A1 EA201171098 A1 EA 201171098A1 EA 201171098 A EA201171098 A EA 201171098A EA 201171098 A EA201171098 A EA 201171098A EA 201171098 A1 EA201171098 A1 EA 201171098A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- diseases
- disorders
- quinolines
- substitute
- sirtuinmodulating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Изобретение относится к 8-замещенным хинолинам и родственным аналогам в качестве сиртуинмодулирующих соединений структурной формулы (I) и способам их применения. Сиртуинмодулирующие соединения можно применять для увеличения продолжительности жизни клетки и лечения и/или предотвращения широкого спектра заболеваний и расстройств, включая, например, заболевания или расстройства, связанные со старением или стрессом, диабет, ожирение, нейродегенеративные заболевания, сердечно-сосудистое заболевание, коагулопатию, воспаление, рак и/или гиперемию, а также заболевания или расстройства, при которых будет полезна повышенная митохондриальная активность. Также настоящее изобретение относится к композициям, содержащим сиртуинмодулирующее соединение в комбинации с другим терапевтическим агентом.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15674909P | 2009-03-02 | 2009-03-02 | |
PCT/US2010/025963 WO2010101949A1 (en) | 2009-03-02 | 2010-03-02 | 8-substituted quinolines and related analogs as sirtuin modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201171098A1 true EA201171098A1 (ru) | 2012-04-30 |
Family
ID=42709991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201171098A EA201171098A1 (ru) | 2009-03-02 | 2010-03-02 | 8-замещенные хинолины и родственные аналоги в качестве модуляторов сиртуина |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2403833A4 (ru) |
JP (1) | JP2012519211A (ru) |
KR (1) | KR20110128908A (ru) |
CN (1) | CN102414180A (ru) |
AU (1) | AU2010221417A1 (ru) |
BR (1) | BRPI1011477A2 (ru) |
CA (1) | CA2754058A1 (ru) |
EA (1) | EA201171098A1 (ru) |
IL (1) | IL214943A0 (ru) |
MX (1) | MX2011009213A (ru) |
WO (1) | WO2010101949A1 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2669943C2 (ru) * | 2013-07-29 | 2018-10-17 | Ф. Хоффманн-Ля Рош Аг | Производные 1,7-нафтиридин-3-карбоксамида, полезные в качестве нейрогенных агентов |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8685970B2 (en) | 2008-05-01 | 2014-04-01 | GlaxoSmithKline, LLC | Quinolines and related analogs as sirtuin modulators |
WO2010003048A1 (en) | 2008-07-03 | 2010-01-07 | Sirtris Pharmaceuticals, Inc. | Benzimidazoles and related analogs as sirtuin modulators |
WO2010037127A1 (en) | 2008-09-29 | 2010-04-01 | Sirtris Pharmaceuticals, Inc. | Chromenone analogs as sirtuin modulators |
CA2779303A1 (en) | 2009-10-29 | 2011-05-19 | Sirtris Pharmaceuticals, Inc. | Bicyclic pyridines and analogs as sirtuin modulators |
EP2571357B1 (en) | 2010-05-21 | 2016-07-06 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
DK2686303T3 (en) | 2011-03-18 | 2016-03-29 | Bayer Ip Gmbh | N- (3-carbamoylphenyl) -1 H -pyrazole-5-carboxamide derivatives and their use for controlling animal pests |
CN102250151B (zh) * | 2011-05-17 | 2013-11-06 | 中国科学院化学研究所 | 2-芳亚胺-8-苯并咪唑喹啉过渡金属配合物及其制备方法与应用 |
SG11201400310WA (en) | 2011-08-29 | 2014-06-27 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
CA2852936A1 (en) | 2011-10-20 | 2013-04-25 | Glaxosmithkline Llc | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
KR20140077964A (ko) * | 2011-10-20 | 2014-06-24 | 글락소스미스클라인 엘엘씨 | 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체 |
CA2865043A1 (en) | 2012-03-13 | 2013-09-19 | Basf Se | Fungicidal pyrimidine compounds |
KR20150085538A (ko) | 2012-11-20 | 2015-07-23 | 에프. 호프만-라 로슈 아게 | 치환된 1,6-나프티리딘 |
DK2970272T3 (en) * | 2013-03-14 | 2019-04-23 | Merck Patent Gmbh | glycosidase |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
WO2014195333A1 (de) | 2013-06-04 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung |
WO2015036059A1 (en) | 2013-09-16 | 2015-03-19 | Basf Se | Fungicidal pyrimidine compounds |
US20160221964A1 (en) | 2013-09-16 | 2016-08-04 | Basf Se | Fungicidal pyrimidine compounds |
US10172915B2 (en) | 2013-10-20 | 2019-01-08 | Duke University | Methods and compositions for activation of sirtuins with Annexin A1 peptides |
JP6112724B2 (ja) * | 2013-10-31 | 2017-04-12 | 日本化薬株式会社 | 1,5−ナフチリジン誘導体およびそれを有効成分として含んでなる殺虫剤 |
CN105764901B (zh) | 2013-11-12 | 2018-06-22 | 豪夫迈·罗氏有限公司 | 作为用于治疗神经变性疾病的神经源性药的吡啶并[4,3-b]吡嗪-2-甲酰胺 |
WO2015107133A1 (de) | 2014-01-20 | 2015-07-23 | Bayer Cropscience Ag | Chinolinderivate als insektizide und akarizide |
CA2939793A1 (en) | 2014-02-19 | 2015-08-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines |
JP6580074B2 (ja) | 2014-05-23 | 2019-09-25 | アクティブ バイオテック エイビー | S100阻害薬として有用な新規化合物 |
CN106817900A (zh) * | 2014-07-17 | 2017-06-09 | 默克专利有限公司 | 新颖的萘啶和异喹啉及其作为cdk8/19抑制剂的用途 |
AU2015295405B2 (en) | 2014-08-01 | 2020-04-09 | Nuevolution A/S | Compounds active towards bromodomains |
MA40532A (fr) | 2014-08-28 | 2021-04-28 | Asceneuron Sa | Inhibiteurs de glycosidases |
CN107001361A (zh) | 2014-12-02 | 2017-08-01 | 拜耳医药股份有限公司 | 杂芳基取代的咪唑并[1,2‑a]吡啶及其用途 |
CN104592109A (zh) * | 2015-01-19 | 2015-05-06 | 湖南华腾制药有限公司 | 一种8-溴喹啉衍生物的制备方法 |
BR112017017032A2 (pt) * | 2015-02-11 | 2018-04-10 | Basilea Pharmaceutica International AG | derivados de mono e poliazanaftaleno substituídos e uso dos mesmos |
SG11201807012QA (en) | 2016-02-25 | 2018-09-27 | Asceneuron S A | Acid addition salts of piperazine derivatives |
US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
AU2017222964B2 (en) | 2016-02-25 | 2020-01-02 | Asceneuron S. A. | Glycosidase inhibitors |
EP3419971B1 (en) | 2016-02-25 | 2022-04-20 | Asceneuron SA | Glycosidase inhibitors |
WO2019037860A1 (en) | 2017-08-24 | 2019-02-28 | Asceneuron S.A. | LINEAR INHIBITORS OF GLYCOSIDASE |
US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
WO2020039029A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Spiro compounds as glycosidase inhibitors |
BR112021017049A2 (pt) * | 2019-02-28 | 2022-02-08 | Kezar Life Sciences | Derivados de tiazol como inibidores de secreção de proteínas |
CN110964011B (zh) * | 2019-12-16 | 2022-06-21 | 诚达药业股份有限公司 | 一种8-氯-1,7-萘啶-3-甲醛的合成方法 |
US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
CR20230057A (es) | 2020-07-02 | 2023-08-15 | Incyte Corp | Compuestos tríciclicos de urea como inhibidores de jak2 v617f |
US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
CA3211748A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
WO2024059216A2 (en) * | 2022-09-15 | 2024-03-21 | Vanderbilt University | 6,6 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same |
WO2024059212A2 (en) * | 2022-09-15 | 2024-03-21 | Vanderbilt University | 6,6 western core compounds as mglu5 negative allosteric modulators and methods of making and using the same |
CN117362286B (zh) * | 2023-12-08 | 2024-03-12 | 清华大学 | 具有sirt6激动活性的化合物及其用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999029318A1 (en) * | 1997-12-11 | 1999-06-17 | Biochem Pharma Inc. | Antiviral compounds |
FR2827599A1 (fr) * | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
SE0103649D0 (sv) * | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic quinoline compounds |
EP1601357A4 (en) * | 2003-03-10 | 2007-10-03 | Schering Corp | HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS |
EP1773834A2 (en) * | 2004-08-03 | 2007-04-18 | Serenex, Inc. | 2, 8-disubstituted naphthyridine derivatives |
WO2006094237A2 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Acridine and quinoline dervatives as sirtuin modulators |
EP2250152A1 (en) * | 2008-02-28 | 2010-11-17 | Novartis AG | Quinolines as inhibitors of farnesyl pyrophosphate synthase |
US8685970B2 (en) * | 2008-05-01 | 2014-04-01 | GlaxoSmithKline, LLC | Quinolines and related analogs as sirtuin modulators |
WO2010037127A1 (en) * | 2008-09-29 | 2010-04-01 | Sirtris Pharmaceuticals, Inc. | Chromenone analogs as sirtuin modulators |
-
2010
- 2010-03-02 CN CN2010800194505A patent/CN102414180A/zh active Pending
- 2010-03-02 AU AU2010221417A patent/AU2010221417A1/en not_active Abandoned
- 2010-03-02 KR KR1020117023017A patent/KR20110128908A/ko not_active Application Discontinuation
- 2010-03-02 BR BRPI1011477A patent/BRPI1011477A2/pt not_active Application Discontinuation
- 2010-03-02 EP EP10749227A patent/EP2403833A4/en not_active Withdrawn
- 2010-03-02 JP JP2011553053A patent/JP2012519211A/ja not_active Withdrawn
- 2010-03-02 EA EA201171098A patent/EA201171098A1/ru unknown
- 2010-03-02 MX MX2011009213A patent/MX2011009213A/es not_active Application Discontinuation
- 2010-03-02 CA CA2754058A patent/CA2754058A1/en not_active Abandoned
- 2010-03-02 WO PCT/US2010/025963 patent/WO2010101949A1/en active Application Filing
-
2011
- 2011-09-01 IL IL214943A patent/IL214943A0/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2669943C2 (ru) * | 2013-07-29 | 2018-10-17 | Ф. Хоффманн-Ля Рош Аг | Производные 1,7-нафтиридин-3-карбоксамида, полезные в качестве нейрогенных агентов |
Also Published As
Publication number | Publication date |
---|---|
JP2012519211A (ja) | 2012-08-23 |
IL214943A0 (en) | 2011-11-30 |
MX2011009213A (es) | 2011-12-14 |
KR20110128908A (ko) | 2011-11-30 |
EP2403833A4 (en) | 2012-08-29 |
BRPI1011477A2 (pt) | 2016-03-22 |
WO2010101949A1 (en) | 2010-09-10 |
CN102414180A (zh) | 2012-04-11 |
EP2403833A1 (en) | 2012-01-11 |
CA2754058A1 (en) | 2010-09-10 |
AU2010221417A1 (en) | 2011-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201171098A1 (ru) | 8-замещенные хинолины и родственные аналоги в качестве модуляторов сиртуина | |
EA201170137A1 (ru) | Бензимидазолы и родственные аналоги в качестве модуляторов сиртуина | |
EA201170847A1 (ru) | Тиазолопиридиновые соединения, регулирующие сиртуин | |
MX2010012961A (es) | Imidazopiridina y analogos relacionados como moduladores de sirtuina. | |
EP2342188A4 (en) | CHROMENONE ANALOGUES AS MODULATORS OF SIRTUIN | |
EA201071263A1 (ru) | Хинолины и их аналоги в качестве модуляторов сиртуина | |
EA201070551A1 (ru) | Сиртуинмодулирующие соединения | |
MX2011006475A (es) | Ftalazinona y analogos relacionados como moduladores de sirtuina. | |
MX2011006084A (es) | Isoindolinona y analogos relacionados como moduladores de sirtuina. | |
AU2014265671A8 (en) | Substituted bridged urea analogs as sirtuin modulators | |
EA201070034A1 (ru) | Модулирующие сиртуин производные имидазотиазола | |
EA201070579A1 (ru) | Солюбилизированные тиазолопиридины | |
EA201071045A1 (ru) | Соединения оксадиазоантрацена для лечения диабета | |
IN2012DN03799A (ru) | ||
EA201690899A1 (ru) | Оксазепины в качестве модуляторов ионных каналов | |
MX2009013977A (es) | Compuestos de tiazolopiridina moduladores de sirtuinas. | |
EA201790417A3 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов | |
EA201070535A1 (ru) | Новые агонисты глюкокортикоидных рецепторов | |
EA201070158A1 (ru) | Сульфонамиды в качестве trpm8 модуляторов | |
EA201391532A1 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов | |
EA201500175A1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
EA201490272A1 (ru) | Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы | |
EA201400976A1 (ru) | Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена | |
EA201791074A1 (ru) | Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина | |
EA201690972A1 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов |